Market Performance - The Hang Seng Index fell by 1.5% last week, closing at 23,916 points[1] - The Hang Seng Tech Index decreased by 2.3%, ending at 5,216 points[1] - Average daily trading volume dropped by 6.1% to HKD 245.4 billion[1] Sector Performance - Consumer discretionary and information technology sectors declined by 2.9% and 2.3% respectively[1] - Healthcare, materials, and real estate sectors increased by 4.9%, 2.6%, and 1.7% respectively[1] Economic Indicators - In June, the U.S. added 147,000 non-farm jobs, with the unemployment rate dropping to 4.1%[2] - Labor force participation rate fell to 62.3%, indicating a potential slowdown in the job market[2] - Average hourly wage growth slowed to 0.2% month-on-month and 3.7% year-on-year, the lowest since May 2021[2] Automotive Sector Insights - Li Auto's June delivery volume fell short of expectations, leading to a 7.9% drop in stock price[3] - Xpeng Motors' new SUV received 10,000 orders within 9 minutes, but concerns over pricing led to a 6.8% decline in stock price[3] - NIO's stock price decreased by 6.6% last week, while CATL's H-shares rose by 9.9% due to stable market share[3] Healthcare Sector Developments - The Hang Seng Healthcare Index rose by 5.0%, outperforming the Hang Seng Index[4] - AstraZeneca is negotiating a potential USD 15 billion licensing deal for a cancer drug with CanSino Biologics[4] Renewable Energy Sector Trends - Solar energy stocks surged, with Xinyi Solar and GCL-Poly Energy rising by 20.4% to 22.8%[5] - Market sentiment is optimistic due to anticipated supportive policies from the government[5] Water Supply Sector Analysis - China Water Affairs reported a 29.9% decline in net profit for FY25, primarily due to credit losses and decreased connection revenue[6][7] - Water supply sales volume increased by 7.4%, with operational revenue rising by 6.5%[7] Real Estate Market Overview - New home sales in 30 major cities fell by 24.7% year-on-year, with a significant drop in first, second, and third-tier cities[11] - Land transaction volume decreased by 55.6% year-on-year, indicating a slowdown in the real estate market[14] Investment Recommendations - The company maintains a "Buy" rating for selected state-owned developers in the real estate sector, anticipating policy support[17][18]

Group 1 - The A-share market showed mixed results with the Chinese Securities Trading Service Hong Kong Biotechnology Index (CESHKB) declining by 2.61% to 7650.23 points, with a trading volume of 9.469 billion [1] - Over the past month, the CESHKB has increased by 15.23%, 28.86% over the last three months, and 75.31% year-to-date [1] - The CESHKB is compiled by the China Securities Index Co., Ltd. under the commission of the China Securities Trading Service Co., Ltd., aiming to reflect the overall performance of biotechnology companies listed in Hong Kong [1] Group 2 - The top ten holdings of the CESHKB include: CanSino Biologics (12.33%), Innovent Biologics (9.95%), WuXi Biologics (9.17%), 3SBio (8.66%), BeiGene (8.57%), Zai Lab (5.79%), WuXi AppTec (5.63%), Kelun-Biotech (5.28%), Ascentage Pharma-B (4.19%), and Kingstar Biotech (4.11%) [1] - The CESHKB's holdings are entirely composed of companies listed on the Hong Kong Stock Exchange, with a 100% representation in the healthcare sector [2]

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [1]. Core Insights - The company is positioned as a leader in the dual antibody sector, spearheading a new era in immuno-oncology with its innovative products, particularly AK104 and AK112, which are nearing commercialization [8][13]. - The revenue forecast indicates significant growth, with projected revenues of 3.672 billion, 5.342 billion, and 7.240 billion CNY for 2025, 2026, and 2027 respectively, reflecting a strong upward trajectory [1][24]. - The company has a robust cash reserve of 7.344 billion CNY, which supports ongoing research and development efforts [29]. Summary by Sections Company Overview - The company focuses on developing innovative antibody drugs and has established a comprehensive drug development platform, ACE, with over 20 product pipelines [13][14]. - It has successfully launched the world's first dual immune checkpoint inhibitor, AK104, for cervical cancer in June 2022, and is expanding its product offerings [13][14]. Financial Performance - The company reported total revenue of 2.124 billion CNY in 2024, with a significant increase in product sales revenue to approximately 2.002 billion CNY, marking a year-on-year growth of 24.88% [24][25]. - The gross profit margin remains high at 86.39%, indicating strong profitability relative to industry standards [25][28]. Product Pipeline - AK104 is the only approved PD-1/CTLA-4 dual antibody globally, with multiple indications approved and ongoing clinical trials for additional cancers [33][34]. - AK112 is also positioned to challenge existing therapies, with promising clinical trial results and a strong market potential [8][19]. Market Position and Future Outlook - The company is expected to achieve a market valuation of 160 billion HKD based on the anticipated revenues from its core products [8]. - The report projects a target price of 163.33 CNY per share, indicating a potential upside from the current market price [8].

Core Viewpoint - The pharmaceutical sector, particularly in Hong Kong, has shown significant growth in the first half of 2025, with the Hang Seng Healthcare Index rising by 47.89% and the A-share pharmaceutical index increasing by 26.74% [1][3]. Summary by Sections Market Performance - As of June 30, 2025, the pharmaceutical sector has experienced a strong rebound, particularly in innovative drugs and CXO segments, following a challenging start to the year [1][2]. - The overall revenue of pharmaceutical companies declined by 4.7% year-on-year in Q1 2025, with net profit dropping by 11.0% due to high base effects from the previous year [1]. Innovative Drug Sector - The innovative drug index has outperformed the broader pharmaceutical index, with a year-to-date increase of 60.87% in the Hong Kong market [3]. - The resurgence of the innovative drug sector is attributed to supportive policies and strong fundamentals, with significant business development (BD) transactions exceeding $50 billion by early June [4][5]. Policy and Regulatory Environment - Recent policies have provided a comprehensive support system for innovative drugs, including adjustments to pricing limits and a shift from price-centric evaluations to multi-dimensional assessments [4]. - The introduction of the "Category C Directory" is expected to facilitate the pricing of effective innovative drugs, enhancing market opportunities [4]. CXO Sector - The CXO sector has also shown positive performance, with the CRO concept index rising by 22.18% year-to-date [6]. - The growth of the CXO sector is closely linked to the performance of innovative drug companies, which are expected to drive demand for CXO services as they advance their research and development pipelines [6][7]. Future Outlook - Analysts remain optimistic about the innovative drug sector's performance in the second half of 2025, with expectations of revenue growth and a reduction in losses for many companies [8][9]. - The focus on large disease categories and the potential for innovative drugs to replace standard therapies are seen as key drivers for future growth [9][10].

Industry Investment Rating - The industry investment rating is "Outperform" [2] Core Views - The report highlights that the PD-(L)1/VEGF bispecific antibody business development (BD) expectations are driving a sustained surge in the innovative drug market. AstraZeneca is in talks for a potential deal worth up to $15 billion with Summit Therapeutics for the PD-1/VEGF bispecific antibody AK112, indicating strong recognition from multinational corporations (MNCs) for this class of drugs [5][14] - The successful launch of Vuxin Qibai monoclonal antibody marks a harvest period for innovative drugs in the gout field, with the market for anti-gout drugs in China expected to grow from 2.2 billion yuan in 2024 to over 10 billion yuan by 2030 [6][32] - The pharmaceutical and biotechnology sector has seen a 3.64% increase, outperforming the CSI 300 index by 2.1 percentage points, ranking 4th among 31 sub-industries [7][41] Summary by Sections Weekly Insights - The report discusses the ongoing excitement in the innovative drug market driven by the PD-(L)1/VEGF bispecific antibody BD expectations and the successful market entry of Vuxin Qibai monoclonal antibody [5][6][14] Subsector Performance - The pharmaceutical and biotechnology sector rose by 3.64%, with other biopharmaceuticals showing the highest increase of 8.28%. The medical device sector experienced the largest decline at 0.21% [7][41][44] Recommended and Benefiting Stocks - Recommended stocks include: - Innovative drugs: Xinda Biopharma, Kangfang Biopharma, and others - Medical devices: Yingke Medical, Maipu Medical, and others - Benefiting stocks: Innovative drugs in H-shares and A-shares, including Zai Lab, Yifang Biopharma, and others [8][40][51]

Core Viewpoint - The rise of the innovative drug sector in the first half of 2025 has become a significant highlight in the investment market, driven by policy support, technological breakthroughs, and market demand, leading to outstanding performance of related funds and marking a critical battle for active equity funds to prove their worth [1][15]. Group 1: Performance of Active Equity Funds - In the first half of 2025, active equity funds have outperformed broad-based indices, with the average return of equity mixed funds at 4.81% and 75% of these funds achieving positive returns [3]. - The top-performing funds in the first half of 2025 include 汇添富香港优势精选A with a return of 86.48%, 中信建投北交所精选两年定开A at 82.45%, and 长城医药产业精选A at 75.18% [5][6]. Group 2: Innovative Drug Sector Growth - The innovative drug sector has experienced explosive growth in the first half of 2025, with the 万得创新药概念指数 rising over 21% and the 恒生创新药指数 increasing by more than 66% [4]. - The top holdings of 汇添富香港优势精选 include stocks like 荣昌生物 and 科伦博泰生物-B, which have shown significant price increases, with 荣昌生物's stock price rising over 370% year-to-date [9][10]. Group 3: ETF Performance - The innovative drug sector has also played a crucial role in the performance of ETFs, with 汇添富国证港股通创新药ETF leading the market with a return of 68.98% [12][13]. - Other notable ETFs in the innovative drug space include 银华国证港股通创新药ETF and 华泰柏瑞恒生创新药ETF, both achieving returns above 67% [12]. Group 4: Long-term Investment Value - The innovative drug industry, after years of stagnation, is now recognized for its market value and commercial potential, highlighting the importance of long-term investment strategies [14][15]. - The historical context shows that since 2010, the A-share market has shifted towards structural opportunities, with sectors like healthcare, consumption, and technology becoming the main drivers of economic growth [20].

Group 1 - The Hong Kong Innovative Drug ETF (159567) closed down 1.44% on July 7, with a trading volume of 1.402 billion yuan [1] - The fund was established on January 3, 2024, with a management fee of 0.50% and a custody fee of 0.10% [1] - As of July 4, 2024, the fund's latest share count was 1.995 billion shares, with a total size of 3.203 billion yuan, reflecting a 404.69% increase in shares and a 747.72% increase in size year-to-date [1] Group 2 - The fund's liquidity showed a cumulative trading amount of 44.415 billion yuan over the last 20 trading days, with an average daily trading amount of 2.221 billion yuan [1] - Year-to-date, the cumulative trading amount reached 96.310 billion yuan over 122 trading days, with an average daily trading amount of 789 million yuan [1] - The current fund manager, Ma Jun, has managed the fund since its inception, achieving a return of 60.51% during the tenure [1] Group 3 - The top holdings of the Hong Kong Innovative Drug ETF include WuXi Biologics (11.47%), BeiGene (10.87%), and Innovent Biologics (9.60%), among others [2] - The fund's holdings are diversified across various companies in the innovative drug sector, with significant investments in both domestic and international firms [2]

Market Overview - A-shares showed mixed performance with the Shanghai Composite Index up 0.32% at 3,472 points, while the Shenzhen Component and ChiNext Index fell by 0.25% and 0.36% respectively[16] - Hong Kong stocks declined, with the Hang Seng Index down 0.64% and the Hang Seng Tech Index down 0.33%, closing below 24,000 points[12] - European markets weakened, with the Stoxx 600 index down 0.72%, amid concerns over US tariff negotiations[10] Economic Policies and Impacts - The "Big and Beautiful" Act signed by Trump is expected to increase US debt pressure, leading to a rise in long-term US Treasury yields[7] - The Act negatively impacts US stock performance in healthcare and renewable energy sectors, while benefiting technology and manufacturing industries[7] - OPEC+ agreed to increase oil production by 548,000 barrels per day in August, exceeding expectations, leading to a drop in oil prices by over 1%[26] Trade and Tariff Developments - The suspension period for "reciprocal tariffs" ends on July 9, with Trump planning to send tariff letters to 12 countries, potentially increasing inflation concerns in the US[10] - The US plans to impose new tariffs ranging from 10% to 70% starting August 1, raising fears of economic repercussions[30] - Trade agreements are being pursued with various countries, including a temporary trade deal with India and a potential agreement with Switzerland regarding drug tariffs[7] Sector Performance - In the US stock market, technology giants and AI sectors are expected to benefit from the new legislation, while traditional energy sectors may see a revival[7] - In the A-share market, banking stocks supported the index, with CITIC Bank rising over 3.7%[16] - The healthcare sector in Hong Kong saw a 1.5% increase, while materials and financial sectors faced declines[12]

Core Viewpoint - The Hong Kong stock market continues to show weakness, particularly in the innovative drug sector, which is experiencing a significant influx of capital despite recent declines in stock prices [1][3][5]. Group 1: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (159570) fell by 1.62%, with a trading volume exceeding 1.65 billion yuan, while it received a net inflow of nearly 16 million yuan during the day [1]. - Over the past ten days, the ETF has attracted over 1.88 billion yuan, bringing its total size to over 8.9 billion yuan, leading its peers in the same category [1]. - Most constituent stocks of the ETF showed negative performance, with notable declines including Rongchang Bio down over 6%, and others like Innovent Biologics and WuXi Biologics down over 4% [3]. Group 2: Policy Support and Investment Trends - Guojin Securities reports that the recent strong performance of innovative drugs is due to multiple factors, including increased policy support for innovative drug development and the encouragement of commercial health insurance to invest in innovative drugs [4][5]. - The National Healthcare Security Administration and the National Health Commission have issued a notice to support high-quality development of innovative drugs, indicating a significant increase in policy support [5]. - The focus on innovative drug business development (BD) remains a key investment theme, especially in light of the global trend of multinational corporations seeking potential blockbuster drugs [7]. Group 3: Investment Opportunities - The potential collaboration between AstraZeneca and Summit Therapeutics, valued at up to 15 billion USD for the AK112 drug, has sparked renewed interest in PD-1/VEGF dual antibodies, highlighting investment opportunities in this area [6]. - The innovative drug sector is expected to benefit from the recent policy measures that will direct healthcare resources towards innovative drugs, accelerating commercialization and profitability for innovative drug companies [7]. - The ETF's underlying assets are entirely focused on the innovative drug industry, with the top ten holdings accounting for nearly 72% of its weight, indicating a strong emphasis on leading companies in this sector [10][11].

Group 1 - The core viewpoint indicates that the Chinese pharmaceutical sector, particularly the innovative drug segment, is poised for a rebound in the second half of the year, with significant growth in the approval of innovative drugs and medical devices [1][2] - As of July 4, the Hong Kong pharmaceutical ETF has seen a net value increase of 71.46% over the past year, reflecting strong market performance [1] - In the first half of the year, China approved 43 innovative drugs and 45 innovative medical devices, marking year-on-year growth of 59% and 87% respectively, showcasing the positive impact of reform policies on industry development [1] Group 2 - The CSI Hong Kong Stock Connect Healthcare Index consists of 50 liquid and large-cap healthcare companies, with the top ten stocks accounting for 59.44% of the index [4] - The top ten weighted stocks in the CSI Hong Kong Stock Connect Healthcare Index include companies like Innovent Biologics and WuXi Biologics, with varying performance in terms of stock price changes [6] - The CSI Medical and Medical Device Innovation Index includes 30 companies with strong profitability and growth potential, with the top ten stocks representing 63.62% of the index [7] Group 3 - The latest scale of the Medical Innovation ETF has reached 1.478 billion yuan, indicating a growing interest in the sector [2] - The performance of individual stocks within the Medical Innovation ETF shows mixed results, with some stocks like TianTan Bio leading gains while others like Sangfor Technologies are experiencing declines [9] - The index aims to reflect the overall performance of profitable and growth-oriented pharmaceutical and medical device companies [7]